Liver Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are older than 18 years of age
- Both men and women are eligible
- People who have tumours that started in the liver or spread to the liver from elsewhere
- People whose cancer is mainly located in the liver
- People who have at least one tumour measuring more than 5.0 cm across at its widest point
- People who have a life expectancy of more than 3 months
- People whose healthy remaining liver volume meets a minimum size requirement (confirm with trial site)
- People who are able to tolerate a series of pre-treatment scans, including a CT scan, a blood vessel imaging procedure, and a nuclear medicine scan involving a specific substance called 99mTc-MAA
- People who are able to attend and tolerate a specialised PET/CT scan after their treatment
- People who are able to attend follow-up scans at 3 months, 6 months, 9 months, 1 year, 2 years, and 3 years after treatment, using either a contrast CT or a specialist MRI scan
Who may not be able to join:
- People whose liver function has declined to a more severe level based on a standard medical scoring system called Child-Pugh (confirm with trial site)
- People with a bilirubin level (a marker of liver function in the blood) above 2 mg/dL
- People with an albumin level (a protein in the blood) below 3.0
- People whose cancer has spread into the main blood vessel supplying the liver
- People with tumours spread across both sides of the liver in multiple locations
- People whose cancer has spread widely to areas outside the liver
- People in whom too much radiation would reach the lungs during treatment, based on pre-treatment measurements
- People who show signs of the treatment substance being absorbed outside the liver
- People who are not able to attend the required follow-up scans after treatment
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Platon Dimopoulos, Resident, University Hospital of Patras
Phone: +306978225019
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Complications; LPFS; Tumor Response
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.